Skip to main content
Premium Trial:

Request an Annual Quote

Symyx Board Rejects 'Final' Certara Offer

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Symyx Technologies today said that its board of directors has rejected Certara's "best and final" offer to acquire Symyx for $5.75 per share in cash, or around $200 million.

It is the third time in the past two weeks that Symyx has declined Certara's bid, saying it does not constitute a superior offer to Accelrys' offer to buy the firm for $5 per share. Symyx has repeatedly said that the deal with Accelrys offers a greater upside and has urged its shareholders to back the merger with Accelrys.

Symyx said that it expects to close the deal with Accelrys, under which shareholders of each firm own around 50 percent of the combined company, at the beginning of July.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.